Complications After Endoscopic Stenting for Malignant Gastric Outlet Obstruction A Cohort StudySterpetti, Antonio V. MD; Fiori, Enrico MD; Sapienza, Paolo MD; Lamazza, Antonietta MDSurgical Laparoscopy Endoscopy & Percutaneous Techniques: June 2019 - Volume 29 - Issue 3 - p 169–172 doi: 10.1097/SLE.0000000000000656 Original Articles Buy Abstract Author InformationAuthors Article MetricsMetrics Background: Gastric stenting has become a common place in clinical practice. The aim of our study was to evaluate the factors influencing the clinical outcome in patients who received endoscopic stenting for malignant gastric outlet obstruction (GOO). Materials and Methods: We prospectively evaluated the clinical course of 87 patients who presented to our attention with malignant GOO. Results: There was neither mortality nor major morbidity after endoscopic stenting. Survival was reduced (average, 2 mo) in patients with an obstruction due to no resectable pancreatic cancer. In patients with primary no resectable pyloric adenocarcinoma, the crude survival was >1 year. Almost half of the patients required a new endoscopy. Food obstruction was common after 6 months from stent placement, limiting the quality of life of the patients. Conclusions: Endoscopic stenting represents a valid treatment in patients with symptoms of GOO from metastatic cancer. Patients with metastatic pyloric adenocarcinoma and normal liver function tests have survival rates longer than 1 year. In this selected group of patients, laparoscopic surgical gastrojejunostomy can be a valid alternative to avoid a close and exhausting follow-up, with the possibility of a better quality of life (res Registry 808). Policlinico Umberto I, University of Rome Sapienza, Rome, Italy The authors declare no conflicts of interest. Reprints: Antonio V. Sterpetti, MD, Policlinico Umberto I, Viale del Policlinico, Rome 00167, Italy (e-mail: email@example.com). Received October 19, 2018 Accepted February 5, 2019 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.